ADELYNN GERSTENBERGER: Open Payments
NPI 1861642910 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$752 in 27 payments from 15 companies in 2025. Trend: 2023 $450 · 2024 $473 · 2025 $752
Food & beverage: $752
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 3 | $151 |
| GENZYME CORPORATION | 1 | $125 |
| Merck Sharp & Dohme LLC | 4 | $84 |
| Daiichi Sankyo Inc. | 3 | $71 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| BeOne Medicines USA, Inc. | 2 | $48 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| Genmab U.S., Inc. | 2 | $36 |
| Janssen Biotech, Inc. | 1 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
Products named: SARCLISA, REBLOZYL, Enhertu, LYNPARZA, BRUKINSA, KISQALI, KEYTRUDA, Tivdak.
Industry payments across NC — which companies pay providers there.
